In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University • EGFR+ • NCI-CCC Thoracic Tumor Board Question

Furthermore, should adding immunotherapy be considered?

Related Questions